Journal
INFECTIOUS DISEASES
Volume 54, Issue 2, Pages 128-133Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/23744235.2021.1982144
Keywords
SARS-CoV2; COVID-19 vaccines; COVID-19 testing; vaccine effectiveness
Categories
Funding
- Lund University
- Swedish Research Council [2019-00198]
- Swedish Research Council and Governmental Funds for Clinical Research
Ask authors/readers for more resources
The study conducted in Southern Sweden found that the effectiveness of the BNT162b2 vaccine against COVID-19 was 86% after the second dose, but only 42% after the first dose. Additionally, individuals with a prior positive test had a 91% effectiveness against new infection when unvaccinated.
Background Vaccine effectiveness against COVID-19 needs to be assessed in diverse real-world population settings. Methods A cohort study of 805,741 residents in Skane county, Southern Sweden, aged 18-64 years, of whom 26,587 received at least one dose of the BNT162b2 vaccine. Incidence rates of COVID-19 were estimated in sex- and age-adjusted analysis and stratified in two-week periods with substantial community spread of the disease. Results The estimated vaccine effectiveness in preventing infection >= 7 days after second dose was 86% (95% CI 72-94%) but only 42% (95% CI 14-63%) >= 14 days after a single dose. No difference in vaccine effectiveness was observed between females and males. Having a prior positive test was associated with 91% (95% CI 85-94%) effectiveness against new infection among the unvaccinated. Conclusion A satisfactory effectiveness of BNT162b2 after the second dose was suggested, but with possibly substantially lower effect before the second dose.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available